4SC AG, of Martinsried, Germany, appointed Enno Spillner chief financial officer.

Aastrom Biosciences Inc., of Ann Arbor, Mich., appointed Stephen Sudovar to its board.

Ablynx, of Ghent, Belgium, appointed Hennie Hoogenboom chief scientific officer.

Acorda Therapeutics Inc., of Hawthorne, N.Y., appointed Gerard Cignarella vice president of business development, and Herbert Henney vice president of medical affairs.

Adaltis Inc., of Montreal, promoted Raymond Tong to chief operating officer.

AdipoGenix Inc., of Boston, appointed Richard Bergman, George Bray and Manuel Navia to its scientific advisory board.

Adventrx Pharmaceuticals Inc., of San Diego, appointed Keith Meister to its board.

Affymax Inc., of Palo Alto, Calif., appointed Philip Haworth vice president of business development.

Altachem Pharma Ltd., of Edmonton, Alberta, appointed Ron Moore, Gilles Lauzon and Ki-Jun Hwang to its scientific advisory board.

Amarin Corp. plc, of London, appointed Anthony Clarke vice president of clinical development at Amarin Neuroscience. It also appointed Prem Lachman nonexecutive director.

ARCH Venture Partners, of Seattle, appointed Steven Gillis venture partner.

ARYx Therapeutics, of Fremont, Calif., appointed Keith Leonard to its board.

BioMarin Pharmaceutical Inc., of Novato, Calif., promoted Jeffrey Cooper to chief financial officer.

Cambridge Biostability Ltd., of Cambridge, UK, appointed John Lambert nonexecutive director of its board.

Cell Therapeutics Inc., of Seattle, promoted Jade Brown to executive vice president and chief business officer, and Scott Stromatt to executive vice president, clinical development and regulatory affairs.

CeMines Inc., of Golden, Colo., appointed Pauline Gee vice president and general manager of the BioSystems division.

Cephalon Inc., of Frazer, Pa., said board member Gail Wilensky was appointed to the World Health Organization's Commission on Social Determinants of Health.

CereMedix Inc., of Maynard, Mass., appointed John Norris to its board.

ChemGenex Pharmaceuticals Ltd., of Melbourne, Australia, appointed Patrick Burns and Peter Bradfield to its board.

Chemokine Therapeutics Corp., of Vancouver, British Columbia, appointed Shahin Rafii to its scientific and clinical advisory boards.

CMEA Ventures, of San Francisco, appointed William Haseltine senior life sciences adviser.

Connetics Corp., of Palo Alto, Calif., appointed Scott Meggs senior director, corporate counsel.

Dendreon Corp., of Seattle, appointed Michelle Burris senior vice president and chief financial officer.

Dynavax Technologies Corp., of Berkeley, Calif., appointed Stanley Plotkin to its board.

Eisai Inc., of Teaneck, N.J., appointed Douglas Snyder vice president and general counsel.

Gemin X Biotechnologies Inc., of Montreal, appointed Timothy Barberich and Wayne Roe to its board.

Genentech Inc., of South San Francisco, appointed Ian Clark senior vice president, commercial operations. Myrtle Potter will serve as a consultant.

No Comments